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Mechanisms of immunogenicity in colorectal cancer
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Background: The immune response in cancer is increasingly understood to be important in determining
clinical outcomes, including responses to cancer therapies. New insights into the mechanisms underpin-
ning the immune microenvironment in colorectal cancer are helping to develop the role of immunother-
apy and suggest targeted approaches to the management of colorectal cancer at all disease stages.
Method: A literature search was performed in PubMed, MEDLINE and Cochrane Library databases
to identify relevant articles. This narrative review discusses the current understanding of the contributors
to immunogenicity in colorectal cancer and potential applications for targeted therapies.
Results: Responsiveness to immunotherapy in colorectal cancer is non-uniform. Several factors, both
germline and tumour-related, are potential determinants of immunogenicity in colorectal cancer. Current
approaches target tumours with high immunogenicity driven by mutations in DNA mismatch repair
genes. Recent work suggests a role for therapies that boost the immune response in tumours with low
immunogenicity.
Conclusion: With the development of promising therapies to boost the innate immune response, there is
significant potential for the expansion of the role of immunotherapy as an adjuvant to surgical treatment
in colorectal cancer.
Paper accepted 12 March 2019
Published online in Wiley Online Library (www.bjs.co.uk). DOI: 10.1002/bjs.11204
Introduction
The tumour microenvironment in colorectal cancer is
influenced by somatic mutational and epigenetic events
that occur during tumour development, as well as by
the host immune system, which exerts negative selection
pressures on tumour cells, by recognition of tumour
antigens as non-self1. Immune checkpoints are a series of
innate and adaptive regulatory mechanisms to modulate
immune activity and promote tolerance to self-antigens.
These can be upregulated in tumours to drive resistance
to immune cell-mediated destruction2,3. Immunotherapy
has been most successful in targeting and blocking these
immune checkpoints, leading to effective antitumour
responses in some cancers4.
The emergence of immunotherapy has transformed
the treatment landscape of some cancers, most notably
cutaneous melanoma5,6 and non-small cell lung cancer
(NSCLC)7,8. So far, the role of immunotherapy in colo-
rectal cancer been limited to the 3–4 per cent of patients
with metastatic disease whose tumours demonstrated
microsatellite instability (MSI)9, due to germline, somatic
or epigenetic inactivation ofDNAmismatch repair (MMR)
genes10. However, its role could be expanded significantly
by drawing on an understanding of the immunogenomic
drivers of the response in the tumour environment.
This review explores current understanding of the rela-
tive contributions of innate immune genomic mechanisms
and somatic mutations to the immune environment in
colorectal cancer, with the implications for potential
expansion of the roles of immunotherapy and other tar-
geted therapies in the management of colorectal cancer at
all disease stages.
Methods
Search strategy
A literature search was conducted using the PubMed,
MEDLINE and Cochrane Library databases, as well
as reference lists from appropriate papers. The goal was
to provide an overview of published research in the field
of colorectal cancer genomics and immunology, with a
particular focus on advances since the launch of the
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genomics era after completion of the Human Genome
Project11. The following keywords were used to perform
flexible searches within these databases: ‘immunother-
apy’, ‘colorectal’ AND ‘cancer’, ‘mutation’, ‘immunity’
and ‘immunologic adjuvants’. Only papers published in
English were included.
Structure
An overview of the role ofMSI in colorectal cancer in delin-
eating clinical outcomes and the response to immunother-
apy is presented, followed by an in-depth consideration
of current understanding of the determinants of the
colorectal tumour environment, including tumour muta-
tional factors, inherited germline determinants and the
potential role of the gut microbiome. The implications
of immune heterogeneity in colorectal cancer and clinical
applications for immunotherapeutic approaches are con-
sidered. There is a strong argument for routine testing
and treatment of patients with colorectal cancer based pri-
marily on immunogenomic rather than histopathological
markers.
Microsatellite instability in colorectal cancer
Approximately 15 per cent of patients with colorectal
cancer have tumours that demonstrate MSI, secondary
to deficientMMR (dMMR).MSI – high (MSI-H) tumours
are characterized by a high mutational burden and the gen-
eration of large numbers of neoantigens, which trigger
powerful anticancer host immune responses12–14. In con-
trast, the 85 per cent of colorectal cancers that develop
owing to chromosomal instability, termed microsatellite
stable (MSS)15, has a much lower mutational burden and
smaller numbers of neoantigens.
More than two variants of MSI-H colorectal cancer have
been demonstrated10,16. Hereditary non-polyposis colonic
cancer or Lynch syndrome is found in 3 per cent of colo-
rectal cancers. It is caused by an inactivating germline
mutation of one or more of the DNAMMR genes (MLH1,
MSH2, MSH6 and PMS2), with a second hit from a spor-
adic mutation, loss of heterozygosity or epigenetic silenc-
ing of a second MMR gene10. These patients have a 50–70
per cent lifetime risk of colorectal cancer, as well as signifi-
cant lifetime risks of endometrial cancer (in women), and
other intestinal and urothelial cancers17. More commonly,
MSI-H tumours have no underlying germline mutations,
and arise as a consequence of epigenetic silencing of the
MMR gene MLH1 by hypermethylation of its promoter
region18. Sporadic MSI-H colorectal cancer is frequently
associated with the v-raf murine sarcoma viral oncogene
homolog B1 (BRAF) V600E mutation, through its associ-
ation with the CpG island methylator phenotype.
BRAF is a downstream molecule in the Rat sarcoma
protein (Ras)–mitogen-associated protein kinase (MAPK)
signalling pathway, which is critical for cell survival and
proliferation19. BRAF mutations are present in both
sporadic MSI-H and MSS colorectal cancers but mostly
absent in Lynch syndrome, and so the presence of a
BRAF mutation, in conjunction with MLH1 methylation
analysis, reliably distinguishes between sporadic MSI-H
colorectal cancer and Lynch syndrome20. A third variant,
Lynch-like syndrome, is less well characterized. Lynch-like
colorectal tumours have no germline MMR gene muta-
tions or hypermethylation of the MLH1 promoter21,
suggesting other unknown somatic mutations within
MMR genes as the cause of MSI10. The revised Bethesda
guidelines for Lynch syndrome diagnosis22 take into
account both clinical information (including diagnosis at
a young age and strong family history) and assessment
of MSI status by immunohistochemistry or genomic
analysis.
MSI-H colorectal cancers have clinicopathological fea-
tures distinct from those of MSS tumours, including an
increased incidence in female patients, more proximal
colonic location, high lymphocyte infiltration levels and
lower incidence of metastasis, with better clinical progno-
sis at stage I–III13,23. A nationwide study24 of 6692 patients
by theDanish Colorectal CancerGroup revealed a reduced
risk of synchronous metastases in patients with dMMR col-
orectal cancer (8⋅0 versus 15⋅8 per cent; odds ratio 0⋅54).
There was also an inverse association between dMMR sta-
tus and lymph node metastasis and venous invasion. How-
ever, in metastatic (stage IV) disease, MSI appears to confer
a worse prognosis25.
MMR loss is associated with the rapid accumulation
of mutations. Timmermann and colleagues26 performed
whole-exome sequencing (WES) of MSI and MSS col-
orectal cancers in two patients, and found 1304 somatic
mutations in the MSI tumour compared to 198 in the
MSS lesion. In addition to base substitutions, large num-
bers of insertions and deletions occur20. They may lead
to frameshifts which, if occurring in tumour suppressor
genes, can drive tumorigenesis. High mutation rates gen-
erate large numbers of new peptides, termed neoantigens,
which are not recognized as self and thus are strongly
immunogenic. Neoantigens contribute to a better progno-
sis in MSI colorectal cancer owing to the increased infiltra-
tion of effector cells (primarily effector T cells27) into the
tumour environment13,23.
Other mechanisms may also contribute towards
immunogenicity in MSI-H colorectal cancer. Constitutive
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS
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activation of the viral response cyclic guanosine–adenosine
3′,5′-cyclic monophosphate synthase–stimulator of inter-
feron genes (cGAS-STING) pathway, with associated T
cell infiltration, occurs in DNA damage response-deficient
breast cancers28. cGAS is activated by DNA damage and
localizes to micronuclei that form during tumorigenesis29.
This triggers a proinflammatory response. Deficiency
in the MMR protein MLH-1 is associated with defi-
cient DNA double-strand break repair and increased
micronuclei formation30, which may also trigger the
cGAS-activated inflammatory response.
Current immunotherapeutic approaches serve primarily
to block immune checkpoints, boosting immune-mediated
tumour destruction31. Patients with dMMR metastatic
colorectal cancer have been shown to have significant clin-
ical responses to immunotherapy with antiprogrammed
cell death 1 (PD-1)/antiprogrammed cell death ligand 1
(PD-L1) treatment in phase II trials21, in stark contrast
to those in the MSS colorectal cancer subgroup where
there was no objective response to immunotherapy32.
Yarchoan and co-workers33 demonstrated a strong cor-
relation between tumour somatic mutation frequency
(and therefore neoantigen burden) and the response to
immunotherapy across a range of human cancer subtypes.
However, MSI status and neoantigen burden do not
sufficiently explain the variability in the colorectal tumour
environment. About 20 per cent of patients in the MSS
colorectal cancer subgroup develop an immunogenomic
signature similar to that in MSI-H colorectal cancer,
despite low mutational burden34. There is evidence that
activating mutations in the Ras–MAPK pathway are asso-
ciated with lower expression of this immune gene cluster
and immune pathway downregulation35–37. In addition,
lymphocytic infiltration, particularly of effector and mem-
ory T cells into the tumour, a key indicator of prognosis in
colorectal cancer27,38, appears to be independent of MSI
status39.
Colorectal cancer tumour microenvironment
Various mechanisms lead to immunosuppression in colo-
rectal cancer. Recruitment of immunoregulatory
cells40, upregulation of inhibitory molecules (includ-
ing myeloid-derived suppressor cells (MDSCs), T
regulatory (Treg) cells, type 2 macrophages and other
cancer-associated cell types2,41–43) and downregulation
of antigen presentation represent methods of immune
evasion44. The alteration of metabolic pathways to favour
glycolysis, even in the presence of sufficient oxygen,
is termed the Warburg effect45. This, along with the
upregulation of anabolic pathways that favour rapid
tumour cell survival and proliferation, often leads to the
generation of an environment that is hostile to T cells
owing to increased acidity, low oxygen levels, competition
for nutrients and the generation of waste substrates44,46.
In this context, T cell exhaustion occurs, defined as the
presence of T cells with decreased cytokine expression and
effector function47,48.
Activated T cells express inhibitory co-receptors, termed
immune checkpoints. The best characterized include
PD-1, cytotoxic T lymphocyte-associated protein 4,
lymphocyte-activation gene 3, T cell immunoglobulin
mucin 3 (Tim-3) and killer immunoglobulin-like receptors.
When they bind to ligands present on antigen-presenting
cells and other cells in the immune environment, they
downgrade the inflammatory response42. This serves as
an innate mechanism to maintain self-tolerance and limit
immune-mediated tissue damage.
Selective upregulation of these immune checkpoints is
often present in MSI-H tumours (Fig. 1). This may explain
why MSI-H tumours are not eliminated naturally despite
high immune activation, and why checkpoint blockade
is effective in these tumours. Tumour infiltrating lymph-
ocytes (TILs) in MSI-H colorectal cancer express high
levels of PD-1, which is absent in MSS colorectal can-
cer. However, corresponding expression of immune check-
point ligands is often absent on tumour cells, and found
to be present on a population of infiltrating myeloid
cells31. Immature populations of myeloid cells (MDSCs)
are present in most tumours and are induced in the pres-
ence of cancer cells49. The upregulation of PD-L1 on these
cells suggests a direct interaction with T cells. They also
appear to increase toxic cell metabolite production and
induce Treg activity, which further suppress effector cell
activity49. Tim-3, which blocks T helper responses, is often
upregulated on exhausted CD4+ and CD8+ TILs in col-
orectal cancer in combination with PD-150. This correlates
with regional metastases and poorer prognoses in both col-
orectal cancer and other solid tumours 51,52.
Clinicopathological data strongly suggest that effector
T cells in the tumour microenvironment are key determi-
nants of outcomes. Patients with large TIL numbers have
improved survival at all disease stages. This prognostica-
tion is superior to that of the UICC TNM classification
by disease stage53. Galon et al.54,55 developed an immuno-
cytochemical score for the colorectal cancer immune
microenvironment, the Immunoscore® (HalioDx, Mar-
seille, France). It is based on the finding that the infiltration
of cytotoxic (CD8+) and memory (CD45RO+) T cells
is associated with improved prognosis. The densities of
CD45RO+ and CD8+ cells in the centre of the tumour
(CT) and invasive margin (IM) are used to stratify patients
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS
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Fig. 1 Immune regulatory pathways in the tumour microenvironment
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into distinct populations with significantly different clinical
outcomes at all disease stages53. In multivariable analysis,
after adjusting for tumour category, differentiation, lymph
node invasion and other molecular biomarkers including
microsatellite status and BRAF mutation status, T cell
infiltration (CD3CT/CD3IM) remained an independent
prognostic factor for disease-free survival (DFS) and
overall survival (OS).
The Immunoscore® was independently validated by the
Society for the Immunotherapy of Cancer worldwide con-
sortium study56,57, in 2681 patients from 14 centres across
13 countries. Similarly, in a study39 across three cohorts,
including 270 colorectal cancer and 3659 pan-cancer sam-
ples from the Cancer Genome Atlas, the Immunoscore®
was a better predictor of disease-specific survival, DFS and
OS than microsatellite status.
Other immune cells contribute to the immune environ-
ment. Natural killer (NK) cells are critical in the innate
immune response and have spontaneous cytotoxic effects
against aberrant cells. There appears to be a decrease inNK
cell activity in patients with colorectal cancer compared
with healthy controls58. In addition, infiltration of NK
cells into colorectal tumours appears to be associated with
better clinical outcomes. In metastatic disease, both a high
proportion of NK cells in peripheral blood and increased
NK cytotoxicity are associated with increased responses
to chemotherapy and longer survival59,60. However, their
interactions withT cells and prognostic significance are not
yet understood. Dendritic cells are key antigen-presenting
cells with a central role in the initiation and regulation of
adaptive immunity. They prime antitumour responses by
presenting tumour antigens to T cells and through inter-
actions with other effector cells. Impairment in dendritic
cell function occurs inmany cancermodels and represents a
mechanism of immune escape61. They also express immune
checkpoint ligands, including PD-L1 and CD80/8662.
Another mechanism for immunosuppression is the
loss of MHC class I and II proteins from cell surfaces.
They are required for antigen presentation to T cells and
other effector cells. Class I loss is frequent in MSI-H
colorectal cancer (60 per cent of cases versus 17 per
cent of MSS colorectal cancers63). Class II expression
is more nuanced. It is expressed in up to 50 per cent of
colorectal cancers. Subsequent loss of class II expres-
sion correlates with reduced TIL density and increased
incidence of regional metastases64. In melanoma, class
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS
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II-negative patients had lower objective response and
survival rates when treated with anti-PD-1/PD-L1
immunotherapy65. Mouse cancer models suggest that
induction of class II expression in colorectal cancer
may improve tumour immunogenicity. Transfection of
the master transcriptional activator of class II (CIITA)
into poorly immunogenic class II-negative adeno-
carcinoma cell lines resulted in these cells developing
robust antigen-processing function, with massive infil-
tration by both CD4+ and CD8+ T cells, and tumour
rejection occurred when the CIITA-transfected cell lines
were infused into mice66,67.
Although immune cell quantificationmethods such as the
Immunoscore® give a phenotypic output of the colorectal
cancer immune environment, the relative contributions of
germline, somatic and epigenetic variations in the immune
signature to this microenvironment have not been deter-
mined. A key question is what drives the presence of large
numbers of TIL in some tumours and not others. It is clear
that somatic mutational factors alone are not sufficient to
explain this variability.
Implications of immune heterogeneity
in colorectal cancer
Colorectal cancer can be divided into four consensus
molecular subtypes (CMS), each with distinguishing
pathological features68. The MSI-H group represents
CMS1, showing hypermutation and strong immune acti-
vation; CMS2 (canonical) shows chromosomal instability
with marked Wnt and myc signalling; CMS3 (epithelial)
shows metabolic dysregulation; and CMS4 (mesenchymal)
shows prominent transforming growth factor β activa-
tion, stromal invasion and angiogenesis. This subtype
demonstrates strong immune cell infiltration.
In a recent study34 using a T helper-1 centric immune
metagene as a marker of the immune contexture, 20 per
cent of patients in the MSS colorectal cancer subgroup
had an immune signature very similar to that of MSI-H
colorectal cancer, despite small numbers of mutations and
fewer neoantigens34. This group segregated to the CMS4
subtype. The Kirsten ras sarcoma oncogene (KRAS) muta-
tion, especially in the CMS2 and 3 subtypes, is associated
with downregulation of immune pathways and reduced
immune cell infiltration35. KRAS mutation, apart from
predicting non-response to antiepidermal growth factor
receptor (EGFR) chemotherapy, is independently associ-
ated with a worse prognosis in colorectal cancer69.
KRAS and BRAF are downstream molecules in
Ras–MAPK signalling, which is a critical mediator of
EGFR-induced signalling cascades70. Mutations that cause
dysregulation and hyperactivation of this pathway71 may be
implicated in suppression of immunogenicity in colorectal
cancer. In a study of triple-negative breast cancer, which
is associated with early metastasis and a worse prognosis
than other variants, alterations in Ras–MAPK signalling
correlated with low TIL numbers, which correlated with
worse recurrence-free survival. Using in vitro and in
vivo mouse-derived breast cancer cell lines, inhibition of
MAPK kinase (MEK), another downstream molecule in
theMAPK signalling cascade, upregulated bothMHCclass
I and II and PD-L1. Combined PD-1/PD-L1 and MEK
inhibition enhanced antitumour immune responses37.
Lochhead and colleagues25 undertook a prospective
observational analysis of the impact of BRAF mutation
status and MSI on 5-year cancer-specific survival in
1253 patients with colorectal cancer. Patients with the
MSI-H/BRAF wild-type subtype had the highest survival
rate (79 per cent), whereas those with the MSS/BRAF
mutant subtype (46 per cent) had the poorest survival.
MSI-H/BRAF mutant and MSS/BRAF wild-type subtypes
had intermediate values (73 and 65 per cent respectively)
with no direct interaction between MSI and BRAF status.
A pooled analysis72 of four phase III studies of first-line
treatment of metastatic colorectal cancer showed a higher
incidence of the BRAF mutation in metastatic MSI
colorectal cancer. Although the BRAF mutation was inde-
pendently associated with a worse prognosis, subanaly-
sis of the MSI-H and MSS colorectal cancer subgroups
established no difference in survival in BRAF mutant and
BRAF wild-type MSI-H colorectal cancers. Metastatic
Lynch and Lynch-like colorectal cancers (in which BRAF
mutations are largely absent) have increased DFS and OS
compared with sporadic MSI colorectal cancer, although
the typically younger age of patients with Lynch syndrome
is a confounding factor16.
Large phase III clinical trials73,74 support a combina-
tion of BRAF and MEK inhibition in melanoma. Disap-
pointingly, these results were not replicated in combination
trials in BRAF-mutated colorectal cancer75, likely due to
the development of escape mechanisms. One possibility is
the heterodimerization of BRAF with CRAF, a BRAF iso-
form, which drives increased Ras–MAPK signalling76, and
has been noted in the development of resistance and sec-
ondary tumours following BRAF inhibition in metastatic
melanoma77,78.
Role of neoantigens in cancer immunotherapy
During tumour evolution, driver mutations, which cause
the transformations required for tumorigenesis and tumour
propagation, and passively acquired passenger mutations
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS
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occur. Neoantigens arise as a result of non-synonymous
somatic mutations during tumour evolution79. They may
be clonal (expressed in all tumour cells) or subclonal
(expressed in a proportion of tumour cells). Tumours
harbouring large numbers of subclonal mutations have
a variety of cell populations with different genomic and,
therefore, phenotypic signatures80. Neoantigen clonal-
ity plays a role in determining the likelihood of a durable
response to immunotherapy. In a series of NSCLC samples
from the Cancer Genome Atlas80, patients with tumours
with high levels of subclonal mutations (and therefore
low neoantigen clonality) had no durable clinical benefit
from immunotherapy, irrespective of the neoantigen load.
Similarly, in a study81 demonstrating the predictive power
of mutational burden for response to pembrolizumab, an
anti-PD-1 inhibitor, its efficacy was dependent on neoanti-
gen clonality. Tumours with similar neoantigen numbers
responded significantly more favourably if neoantigens
were clonal than if they were subclonal.
The most potent T cell responses are against
neoantigens82. As the pattern of mutations is highly
variable, and the cancer genome is unique to each individ-
ual, identification of neoantigens was challenging initially.
With the development of next-generation sequencing and
bioinformatics strategies for in silico prediction, it is now
possible to rapidly identify and filter neoantigens83–85.
WES of tumour samples allows identification of somatic
mutations, which are modelled using a protein prediction
algorithm86 and fed into an MHC-binding predictor to
model the MHC-binding capacity87–89. Structural vari-
ants (in particular, gene fusions that may also generate
neoantigens) are more difficult to identify from WES
unless RNA sequencing data are available90.
Proposed advantages of targeted cancer immunotherapy
include increased efficacy and specificity, resulting in lower
toxicity than current treatments. Current approaches
involve either boosting the T cell response to tumour
neoantigens (adoptive cell transfer and checkpoint block-
ade are examples of this) or altering the neoantigen
landscape to favour the expression of those that are
highly immunogenic90. Adoptive cell transfer of T cells
recognizing certain tumour antigens has been shown to
induce tumour regression in some trials, most notably
in melanoma91. In a clinical trial92 in three patients with
melanoma, WES was used to identify the highest binding
epitope peptides and these patients were vaccinated with
autologous dendritic cells that had been pulsed with the
top seven highest binding peptides identified from each
tumour. This led to an increase in the breadth and diversity
of neoantigen-specific T cells from all patients, who were
alive with no adverse autoimmune events at the time of
reporting. The potential for use in solid tumours, such as
breast cancer, is being explored93.
Tumour neoantigens are ideal targets for cancer
immunotherapy, as they are expressed only in tumour
cells and so are less likely to induce either immunological
tolerance or toxicity from targeted therapy. However,
targeting specific neoantigens may lead to tumour escape
via expansion of subclonal populations. It remains uncer-
tain whether cancer vaccination is potent enough to
induce remission in solid tumours. Other limiting factors
include the significant financial implications inherent in
developing personalized treatments, and the possibility
of significant adverse reactions. Nevertheless, there are
encouraging results from initial studies, and refinements
in neoantigen targeting and vaccine delivery are ongoing.
Applications of immunotherapy in colorectal
cancer
Phase I trials of immunotherapy in patients with advanced
colorectal cancer showed poor results, with little objec-
tive clinical response or improvement in outcomes94,95.
However, further studies showed clear differences in
those with dMMR/MSI-H colorectal cancer. Le et al.32
compared outcomes in patients with or without dMMR
colorectal cancer who were given pembrolizumab. The
immune-related objective response rate (ORR) was 40
per cent and the progression-free survival (PFS) rate 78
per cent in patients with dMMR, compared with 0 and
11 per cent respectively in patients without dMMR. This
was associated with a significantly reduced risk of death
or disease progression (hazard ratio 0⋅22) in the dMMR
group. High levels of somatic mutations also correlated
with improved survival32.
Current trials9,96 have not shown significant differ-
ences in ORR and disease control in Lynch versus
non-Lynch-associated tumours. Le and colleagues96
observed no significant difference in ORR, deter-
mined radiologically and clinically, between Lynch and
non-Lynch syndrome-associated MSI-H tumours (46 and
59 per cent respectively; P= 0⋅27). In the Keynote-142
phase II open-label trial9 of nivolumab, an anti-PD1 anti-
body, in patients with metastatic MSI-H colorectal cancer
who had been unable to tolerate previous chemotherapy
or whose disease had progressed, ORR and disease control
rates were similar in Lynch versus non-Lynch MSI-H
colorectal cancer (33 versus 29 per cent, and 70 versus 75
per cent, respectively).
Based on data fromfive single-armmulticohortmulticen-
tre trials, in 2017 the US Food and Drug Administration97
granted accelerated approval for use of the anti-PD-1
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS
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Table 1 Clinical trials of immunotherapy in colorectal cancer
Reference (trial) Phase Regimen Subgroups Outcomes Duration
Le et al.32 II Pembrolizumab (PD-1 inhibitor) dMMR/MSI-H versus MSS CRC Immune-related objective
response rate
PFS
20weeks
Overman et al.9
(CheckMate 142)
II Nivolumab (PD-1 inhibitor) +/–
ipilimumab (CTLA-4 inhibitor)
Metastatic pretreated
dMMR/MSI-H CRC
Immune-related objective
response rate
PFS
OS
12months
Mettu et al.99
(BACCI)
II Capecitabine/bevacizumab
+/–atezolizumab (PD-L1
inhibitor)
Metastatic CRC PFS
OS
Ongoing
Hoffmann-La Roche100
(COTEZO IMblaze370)
III Cobimetinib + atezolizumab
(PD-L1 inhibitor) versus
atezolizumab monotherapy
versus regorafenib
Heavily pretreated locally
advanced or metastatic CRC
(> 95% MSS)
OS
PFS
3 years
Diaz et al.101 (KEYNOTE-177) III Pembrolizumab (PD-1 inhibitor)
versus standard chemotherapy
dMMR/MSI-H stage IV CRC PFS
OS
57months
Asan Medical Centre102
(POLE-M)
III Standard 5-FU-based adjuvant
chemotherapy +/–sequential
avelumab (PD-L1 inhibitor)
Resected stage III dMMR/MSI-H
or POLE-mutant colonic cancer
DFS 5 years
Sinicrope et al.103 (ATOMIC,
Alliance A021502)
III Combination chemotherapy +/–
atezolizumab (anti-PD-L1)
continued as monotherapy for
additional 6months
Resected stage III dMMR/MSI-H
colonic carcinomas
DFS
OS
Adverse events
5 years
Tabernero et al.104 I CEA-TCB antibody +/–
atezolizumab (anti-PD-L1)
Heavily pretreated metastatic CRC
(mainly MSS)
Adverse events
Antitumour activity (RECIST
version 1.1 criteria105)
PFS
40months
PD-1, programmed cell death protein 1; dMMR, deficient mismatch repair; MSI-H, microsatellite instability –high; MSS, microsatellite stable; CRC,
colorectal cancer; PFS, progression-free survival; CTLA-4, cytotoxic T lymphocyte-associated protein 4; OS, overall survival; PD-L1, programmed cell
death protein ligand 1; POLE-M, mutated DNA polymerase ε; 5-FU, 5-fluorouracil; DFS, disease-free survival; CEA-TCB, carcinoembryonic antigen–T
cell-bispecific; RECIST, Response Evaluation Criteria in Solid Tumours.
inhibitor pembrolizumab in people with unresectable or
MSI-H or dMMR solid tumours. Several ongoing clini-
cal trials are assessing checkpoint blockade agents in colo-
rectal cancer. Patients in these trials all have advanced or
metastatic disease (MSI-H andMSS) and have been heavily
pretreated32,98–103 (Table 1).
Meta-analysis106 of eight clinical trials of immunotherapy
with PD-1/PD-L1 blockade has shown that the PD-L1
expression level in tumour samples has neither prognos-
tic nor predictive significance in determining outcomes.
These were studies of advanced urothelial and head-
and-neck tumours. Similar findings were reported from
a study32 comparing outcomes after treatment with pem-
brolizumab in MSI-H andMSS colorectal cancers. PD-L1
expression was detected only in MSI-H tumours, but there
was no correlation between PD-L1 levels and PFS or OS.
Another approach is to stimulate immunogenicity within
the tumour, for example, by the use of T cell-targeted
bispecific antibodies107. Bacac and co-workers108 assessed
carcinoembryonic antigen–T cell-bispecific (CEA-TCB)
antibody, which binds simultaneously to CD3 expressed
on T cells and CEA, a marker often overexpressed in
colorectal cancer. CEA-TCB antibody activity drives
T cell proliferation and cytokine release, converting a
poorly immunogenic tumour microenvironment into an
inflamed one108. Thus, CEA-TCB antibody can enhance
the effect of immune checkpoint blockade agents, even
in MSS tumours. A phase I study104 assessing the effect
of combination treatment with a novel CEA-TCB anti-
body (RO6958688) and PD-L1 inhibitor (atezolizumab)
in patients with heavily pretreated metastatic colorectal
cancer showed increased tumour inflammation and radi-
ological evidence of tumour reduction in patients with
both MSI-H and MSS colorectal cancer treated with
higher-dose combination therapy (Table 1).
Radiotherapy may also stimulate neoantigen generation.
Radiation triggers local and systemic immune effects by
inducing lethal DNA damage, which increases the vis-
ibility of tumour to the host immune environment109.
The abscopal effect, in which tumour regression occurs
at a site distant from the local radiotherapy field, is com-
monly observed following radiotherapy110. Immune cell
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS
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infiltration into the tumour environment is crucial for this
response and is often lacking in the presence of systemic
immunosuppression111,112. Case reports have suggested
significant clinical benefit in combined immunotherapy
and radiotherapy, notably in melanoma113. The PACIFIC
trial114, a phase III randomized trial of the PD-L1 antibody
durvalumab as consolidation therapy after radiotherapy
in NSCLC, showed significant improvement in PFS
with durvalumab compared with placebo (16⋅8 versus
5⋅6months). However, the potential for toxicity must
be addressed. Combination therapy may generate both
tumour-specific and non-tumour-specific antigens, which
may induce autoimmune responses115. Furthermore,
radiotherapy is established in the treatment of rectal
cancer116, but is not suitable for colonic tumours,
which represent 60–70 per cent of the colorectal disease
burden117,118.
Currently, the only immunotherapeutic agents licensed
for use in advanced colorectal cancer with dMMR target
the programmed cell death pathway119. There is signifi-
cant potential to identify subgroups of patients who may
respond to specific immunotherapeutic agents targeting
other immune cell-driven pathways. Inmouse solid tumour
models, targeting both Tim-3 and PD-1 leads to greater
antitumour responses than targeting either pathway
separately120. Combined Tim-3 and PD-1 blockade is
currently in early-phase clinical trials in solid tumours121.
Bispecific antibodies show promise in boosting the innate
immune response. In addition, the effects of neoantigen
clonality in determining the immune microenvironment
may provide opportunities to refine the targets employed
in cancer vaccination and adoptive cell transfer, potentially
making these valuable adjuncts to surgical treatment in
colorectal cancer.
Germline determinants of immunogenicity
in colorectal cancer
In contrast to exploration of the role of tumour neoanti-
gens in determining immunogenicity in colorectal cancer,
the contribution of inherited, germline differences
in immune gene expression to the immune landscape
is relatively underexplored. A key development has
been the expansion of expression quantitative trait locus
(eQTL) studies. eQTLs are single-nucleotide polymor-
phisms (SNPs) usually found in non-coding regions of the
genome, which influence gene expression. They may be
cis (found in close proximity to the genes they affect) or
trans (found at distance from the genes they affect, or even
on separate chromosomes)122–124 (Fig. 2).
Repositories of eQTL data, such as the Multiple Tissue
Human Expression Resource (MuTHER) project125 and
the Genotype–Tissue Expression Project (GTEx)126,127,
have facilitated exploration of the influence of eQTLs
in determining the expression of phenotypes of inter-
est, including complex diseases and cancer128–132 (Table 2).
Fig. 2 Schematic representation of cis- and trans-expression quantitative trait locus effects on targeted genes
Gene A
Gene A
Gene B
SNP Y
TSS < 1Mb
SNP X
a  Cis-eQTL
b  Trans-eQTL
Chromosome A
Chromosome A
Chromosome B
a Cis-expression quantitative trait locus (eQTL) single-nucleotide polymorphism (SNP) effect on gene A; b trans-eQTL effect on gene B on a different
chromosome. TSS, transcription start site.
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Table 2 Large-scale human expression quantitative trait locus repositories
Project name Data repository eQTL Tissue subtypes Sample size
MuTHER http://www.muther.ac.uk/Data.html Cis LCL, skin, adipose 856
GTEx https://www.gtexportal.org/home/ Cis Multiple 237
Childhood asthma
studies128,129
http://csg.sph.umich.edu/liang/imputation/ Cis and trans EBVL 2642
International HapMap
Project130
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6536 Cis and trans LCL 270
Gilad/Pritchard Group http://eqtl.uchicago.edu/Home.html Cis and trans LCL, liver, brain
Pickrell Lab http://gwas-browser.nygenome.org Cis and trans Multiple Combined
sources131
Geuvadis Project https://www.ebi.ac.uk/Tools/geuvadis-das/ Cis LCL 465
Blood eQTL132 https://genenetwork.nl/bloodeqtlbrowser/ Cis and trans Peripheral blood 5311
eQTL, expression quantitative trait locus; MuTHER, Multiple Tissue Human Expression Resource Project; LCL, lymphoblastoid cell lines; GTEx,
Genotype–Tissue Expression Project; EBVL, Epstein–Barr virus-transformed cell lines.
Vogelsang et al.133 used data from theMuTHER project to
identify immune gene eQTLs and correlate these with out-
comes in cutaneous melanoma. Of the 382 immunomod-
ulatory genes selected, SNP genotyping of the 50 most
significant cis-eQTLs in the MuTHER lymphoblastoid
cell line database was performed and correlated with out-
come. Two SNPs identified were highly correlated with
OS, one affecting interleukin 19 expression and the other
BATF3 expression. Landmark-Høyvik and colleagues134
showed that the expression of MHC class I and II genes
in breast cancer survivors was associated with SNPs in 100
genes. Comparison with a matched healthy cohort revealed
specific associations with genes enriched for immune sys-
tem processes. Although the predictive value of these
eQTLs has not yet been explored, the detection of rele-
vant immune genes in patients with colorectal cancer and
interrogation of their biological roles will provide further
targets for therapy.
Gut microbiome in colorectal immunogenicity
Interactions between gut microbiota, the evolution of colo-
rectal cancer and responses to therapy are complex. In ani-
mal models, specific microbes associated with colonic
inflammation can drive carcinogenesis. Bacteroides frag-
ilis rapidly induces colitis and colonic tumours in mice
heterozygous for the adenomatous polyposis coli gene,
with marked downregulation of effector T cell responses
and upregulation of Treg responses135. In patients with
colorectal cancer, there is a large degree of heterogeneity
in gut microbiota composition, with differences between
faecal and mucosal samples, and between proximal and
distal tumours136. However, the gut microbiota differ
significantly between patients with colorectal cancer and
healthy controls136. It is uncertain whether these altered
microbiota are drivers of carcinogenesis rather than pas-
sengers, reflecting the immune responses occurring within
the colonic mucosa.
Routy and colleagues137,138 showed that abnormal
gut microbiome composition could be responsible for
non-response to anti-PD-1 immunotherapy in patients
with a range of epithelial cancers, mainly NSCLC and
renal cell carcinoma. Systemic antibiotic treatment,
which alters the gut microbiome, just before commenc-
ing immunotherapy led to worsened PFS and OS than
that in a comparable non-treated group. Differences in
microbe profiles were noted, with an abundance of Akker-
mansia municiphilia and Alistipes indistinctus in responders
to immunotherapy. Furthermore, faecal mucosal trans-
plantation (FMT) from responders into germ-free or
antibiotic-treated mouse tumour models led to significant
antitumour responses, with upregulation of dendritic cell
and effector T cell responses. This did not occur with FMT
from non-responders137. In metastatic melanoma, micro-
biota in responders to immunotherapy demonstrated an
abundance of Bifidobacterium longum, Collinsella aerofaciens
and Enterococcus faecium, whereas non-responders had an
abundance of Ruminococcus obeum and Roseburia intestinalis.
A germ-free mouse tumour model also demonstrated simi-
lar responses to FMT from responders139. The translation
of these findings into clinical studies, and into patients with
colorectal cancer is an exciting potential avenue of interest.
Overview
Advances in genetics and cancer immunology have
improved understanding of the drivers of immunogenicity
in cancer and potential mechanisms for treatment, particu-
larly in cancers that are refractory to current therapies. The
role of immunotherapy in colorectal cancer in particular is
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expanding. Recent guidelines140,141 mandate testing biopsy
or resected specimens from all patients with colorectal
cancer for Lynch syndrome. This involves a genomic or
immunohistochemical screen for MSI, followed by further
BRAF mutational andMLH1 hypermethylation analysis to
distinguish Lynch from non-Lynch colorectal cancer. The
emphasis is on making the diagnosis of Lynch syndrome to
facilitate intensive screening to improve clinical outcomes.
However, screening is not universal and guidelines often
limit this to patients aged less than 70 years140,141. Given
the prognostic differences in MSI and MSS colorectal can-
cer outcomes, and the potential for expansion of the role
of immunotherapy in this patient group, this information
is critically relevant even in those with sporadic MSI-H
colorectal cancer.
For those with MSS colorectal cancer, there are cur-
rently no clinically applicable immunogenomic tests to
determine the efficacy of immunotherapy. Immunohis-
tochemical markers such as the Immunoscore® and data
from genome sequencing have shown the clear potential
to identify other equally beneficial markers. In addition,
adjuvant methods to boost immunogenicity show signif-
icant promise. Although many aspects of these therapies
are in their infancy, the potential for the development and
application of targeted treatments with greater efficacy
and reduced toxicity is attractive. It is anticipated that
refined and targeted immune therapies will become part
of standard treatment regimens in patients with colorectal
cancer at all disease stages.
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